ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Rating of “Buy” by Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have earned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $38.67.

A number of research firms have issued reports on ABVX. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

ABIVAX Société Anonyme Price Performance

NASDAQ:ABVX opened at $5.92 on Friday. The business has a fifty day simple moving average of $6.75 and a two-hundred day simple moving average of $8.79. ABIVAX Société Anonyme has a 1 year low of $5.50 and a 1 year high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several large investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 190.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock valued at $11,078,000 after buying an additional 991,781 shares during the period. Franklin Resources Inc. boosted its stake in ABIVAX Société Anonyme by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after buying an additional 141,710 shares during the period. Nantahala Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock valued at $10,512,000 after buying an additional 450,413 shares during the period. Millennium Management LLC boosted its stake in ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after buying an additional 285,542 shares during the period. Finally, Citadel Advisors LLC boosted its stake in ABIVAX Société Anonyme by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after buying an additional 389,247 shares during the period. Institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.